Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "Global Cancer Stem Cells Market by Type (Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell), Source (Allogenic, Autologous), Cancer Type, Application, End-User - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The Cancer Stem Cells Market grew from USD 4.72 billion in 2023 to USD 5.21 billion in 2024. It is expected to continue growing at a CAGR of 10.55%, reaching USD 9.54 billion by 2030.
Understanding cancer stem cells is crucial for developing more effective cancer treatments. The global increase in cancer cases continues to drive demand for innovative treatments. Cancer stem cells (CSCs) are crucial in cancer initiation and recurrence, making products targeting these cells essential. The growing understanding of their role in cancer progression has increased the demand for therapies and diagnostics focusing on cancer stem cells. However, strict regulations associated with the approvals and lack of standardization protocols are significant challenges the companies face. Moreover, innovations in stem cell research, genomics, and biotechnology have propelled forward the methods available for studying CSCs. Integrating gene therapy techniques with CSC research offers promising avenues for eradicating CSCs at the genetic level.
In the Americas, particularly the United States and Canada, there is a high prevalence of cancer, which has supported a strong infrastructure for cancer research, including studies on cancer stem cells. Both countries exhibit advanced healthcare systems and significant investments in biotechnology research. The United States leads in global cancer stem cell research due to substantial government and private funding. Numerous patents have been filed in the United States concerning cancer stem cell therapies and diagnostics innovations.
European Union countries maintain a robust framework for cancer research facilitated by support from various EU policies and funding mechanisms, such as Horizon Europe. The EU's interest in personalized medicine has led to increased attention on cancer stem cells, considering their role in the efficacy of individualized treatment plans. There are ongoing investments in exploring novel therapies that target these cells.
Moreover, the Asia Pacific region represents a dynamic area for cancer stem cell research, showcasing significant activity in terms of patents, particularly in China and Japan. Both countries have strong national policies supporting biotechnology and medical research, with substantial government funding. Japan, known for its rapid technology adoption, shows a considerable consumer willingness to invest in advanced medical treatments.
China has seen a surge in research activities and market opportunities for cancer stem cell therapies. India is also making strides, with increased investment in healthcare and cancer research, though it still faces challenges related to infrastructure and public health priorities.
Market Dynamics
Market Drivers
- Growing awareness of cancer worldwide and the need for effective therapeutic options
- Supportive government policies and incentives for stem cell research
Market Restraints
- Stringent regulatory frameworks for stem cell research
Market Opportunities
- Innovations in genomics sequencing and biotechnology for cancer research
- Increased collaboration between academic institutions and biopharmaceutical companies for stem cell research
Market Challenges
- Complexities associated with the heterogeneity and plasticity of cancer stem cells
Market Segmentation Analysis
- Type: Utilization of hESCs in cancer biology to understand cancer mechanisms and support the development of targeted cancer therapies
- Cancer Type: Increasing usage of cancer stem cells in varied cancer diagnoses to necessitates effective treatments and therapies
Recent Developments
StemCell Technologies Enhances Portfolio with Propagenix Acquisition to Advance Cancer Stem Cell Research
StemCell Technologies, a player in the biotechnology sector, has strategically acquired Propagenix, a company well-regarded for its innovative cell propagation technologies. This acquisition is set to significantly bolster StemCell Technologies' capabilities in cancer stem cell research. Propagenix has developed a unique technology that simplifies and enhances the growth of primary human epithelial cells, which are crucial for cancer research. By integrating these advanced methods, StemCell Technologies aims to accelerate the development of more effective cancer treatments.
AstraZeneca Enhances Cell Therapy Capabilities with Gracell Biotechnologies Acquisition
AstraZeneca announced the acquisition of Gracell Biotechnologies, marking a significant expansion in its oncology and autoimmune disease treatment sectors. This strategic move aims to harness Gracell's innovative cell therapy technologies, which include efficient, cost-effective methods of producing genetically modified cell therapies. Such therapies are crucial for treating various cancer types and autoimmune disorders effectively. AstraZeneca's acquisition is poised to boost its research capabilities while potentially accelerating the delivery of new, transformative treatment options to patients worldwide. This partnership underscores AstraZeneca's commitment to advancing healthcare through cutting-edge biotechnological innovations.
Max Healthcare Initiates Advanced CAR-T Cell Therapy in Partnership with ImmunoACT
Max Healthcare introduced Chimeric Antigen Receptor T-cell (CAR-T) therapy for patients. This innovative cancer treatment is a result of their collaboration with ImmunoACT, demonstrating a significant leap in cancer care technology in the region. CAR-T therapy, a form of immunotherapy, utilizes genetically modified T-cells from the patient's immune system to effectively target and eliminate cancer cells. This treatment has primarily been utilized for blood cancers, such as lymphoma and leukemia, and its introduction in India marks a pivotal advancement, providing new hope for patients and potentially heralding a new era in the treatment of resistant and relapsed cases of cancer.
Companies Featured
- AcceGen
- Becton, Dickinson
- Bio-Techne
- Biorestorative Therapies.
- BrainStorm Cell
- Gamida Cell
- GenScript Biotech
- JCR Pharmaceuticals
- Lonza Group
- Merck
- Miltenyi Biotec
- Novartis
- Qiagen
- Sartorius
- STEMCELL Technologies Canada
- Takara Bio Inc.
- Takeda Pharmaceutical
- Thermo Fisher Scientific
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 183 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $5.21 Billion |
| Forecasted Market Value (USD) by 2030 | $9.54 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.2. Market Segmentation Analysis
5.2.1. Type: Utilization of hESCs in cancer biology to understand cancer mechanisms and support the development of targeted cancer therapies
5.2.2. Cancer Type: Increasing usage of cancer stem cells in varied cancer diagnoses to necessitates effective treatments and therapies
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Cancer Stem Cells Market, by Type
- Adult Stem Cell
- Human Embryonic Stem Cell
- Induced Pluripotent Stem Cel
7. Cancer Stem Cells Market, by Source
- Allogenic
- Autologous
8. Cancer Stem Cells Market, by Cancer Type
- Breast Cancer
- Lung Cancer
- Prostate Cancer
9. Cancer Stem Cells Market, by Application
- Clinical Research
- Drug Development
- Targeted Therapy
10. Cancer Stem Cells Market, by End-User
- Academic & Research Institutes
- Hospitals & Cell Banks
- Pharmaceutical & Biotechnology Companies
11. Americas Cancer Stem Cells Market
12. Asia-Pacific Cancer Stem Cells Market
13. Europe, Middle East & Africa Cancer Stem Cells Market
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. StemCell Technologies Enhances Portfolio with Propagenix Acquisition to Advance Cancer Stem Cell Research
14.3.2. AstraZeneca Enhances Cell Therapy Capabilities with Gracell Biotechnologies Acquisition
14.3.3. Max Healthcare Initiates Advanced CAR-T Cell Therapy in Partnership with ImmunoACT
14.4. Strategy Analysis & Recommendation
15. Competitive Portfolio
For more information about this report visit https://www.researchandmarkets.com/r/wmwj3r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
